Frank A. Ahmann

LoneStar Heart, Inc. develops cardiac restorative therapies for patients with heart failure. The firm functions in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. Its flagship product is Algisyl-LVR, a medical device under clinical development intended to prevent or reverse the progression of advanced heart failure in patients who have an enlarged left ventricle. The company was founded in June 2010 by James T. Willerson, Eric N. Olson and Olav B. Bergheim and is headquartered in Laguna Hills, CA.

Medpace Research, Inc. is a pharmaceutical company, which focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. The company was founded by Billy G. Hudson, J. Wesley Fox Ahmann and Tryggvason Karl on May 25, 2004 and is headquartered in Cincinnati, OH.

Allvivo, Inc. develops & sells proprietary coated devices and novel biotechnology surfactants for the burgeoning proteomics, biologics and bioscience segments of the life sciences industry. The company was founded in December, 1999 and is headquartered in Lake Forest, CA.

CardioPolymers, Inc. provides novel biocompatible polymer implant therapies to treat cronic heart failures. The company was founded in 2003 and is headquartered in Laguna Hills, CA.

Recardio, Inc. operates as a clinical-stage life science company that focuses on therapies for cardiovascular, oncology, and infectious diseases. The company was founded by Roman Schenk and is headquartered in San Francisco, CA.

Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022.